tradingkey.logo

Trinity Biotech PLC

TRIB
0.800USD
+0.092+13.06%
Cierre 02/06, 16:00ETCotizaciones retrasadas 15 min
15.41MCap. mercado
PérdidaP/E TTM

Trinity Biotech PLC

0.800
+0.092+13.06%

Más Datos de Trinity Biotech PLC Compañía

Trinity Biotech plc is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemical parameters in serum, plasma and whole blood, and the Company intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its TrinScreen Human Immunodeficiency Virus (HIV) rapid point-of-care test is a high-quality, single-use immunoassays to aid in the diagnosis of HIV. The Uni-Gold range of rapid point-of-care test devices consist of high-quality, single-use immunoassays to aid in the diagnosis of HIV.

Información de Trinity Biotech PLC

Símbolo de cotizaciónTRIB
Nombre de la empresaTrinity Biotech PLC
Fecha de salida a bolsaOct 21, 1992
Director ejecutivoGillard (John)
Número de empleados- -
Tipo de seguridadDepository Receipt
Fin del año fiscalOct 21
DirecciónIda Business Park, Bray, Co Wicklow
CiudadDUBLIN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísIreland
Código postal18
Teléfono01135312955111
Sitio Webhttps://www.trinitybiotech.com/
Símbolo de cotizaciónTRIB
Fecha de salida a bolsaOct 21, 1992
Director ejecutivoGillard (John)

Ejecutivos de Trinity Biotech PLC

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Ronan O'caoimh
Mr. Ronan O'caoimh
Founder, Executive Director
Founder, Executive Director
--
--
Dr. James (Jim) Walsh, Ph.D.
Dr. James (Jim) Walsh, Ph.D.
Executive Director - Business Development
Executive Director - Business Development
--
--
Mr. John Gillard
Mr. John Gillard
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Ms. Eibhlin Kelly
Ms. Eibhlin Kelly
Chief Information Officer
Chief Information Officer
--
--
Mr. Tom Lindsay
Mr. Tom Lindsay
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Gary Keating, Ph.D.
Dr. Gary Keating, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--
Mr. Colm Molloy
Mr. Colm Molloy
Group Director of Human Resources and Culture
Group Director of Human Resources and Culture
--
--
Mr. Eric Ribner
Mr. Eric Ribner
Investors Relations
Investors Relations
--
--
Mr. Andrew Omidvar, Ph.D.
Mr. Andrew Omidvar, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Susan O'Connor
Ms. Susan O'Connor
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Ronan O'caoimh
Mr. Ronan O'caoimh
Founder, Executive Director
Founder, Executive Director
--
--
Dr. James (Jim) Walsh, Ph.D.
Dr. James (Jim) Walsh, Ph.D.
Executive Director - Business Development
Executive Director - Business Development
--
--
Mr. John Gillard
Mr. John Gillard
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Ms. Eibhlin Kelly
Ms. Eibhlin Kelly
Chief Information Officer
Chief Information Officer
--
--
Mr. Tom Lindsay
Mr. Tom Lindsay
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Gary Keating, Ph.D.
Dr. Gary Keating, Ph.D.
Chief Technology Officer
Chief Technology Officer
--
--

Desglose de ingresos

Divisa: USDActualizado: mar., 6 de ene
Divisa: USDActualizado: mar., 6 de ene
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Por negocioUSD
Nombre
Ganancia
Proporción
Clinical Laboratory
42.29M
74.41%
Point of care
9.09M
16.00%
Laboratory services
5.45M
9.59%
Por regiónUSD
Nombre
Ganancia
Proporción
Americas
44.98M
79.15%
Ireland
11.85M
20.85%
Eliminations
0.00
0.00%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Clinical Laboratory
42.29M
74.41%
Point of care
9.09M
16.00%
Laboratory services
5.45M
9.59%

Estadísticas de accionistas

Actualizado: dom., 1 de feb
Actualizado: dom., 1 de feb
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
MiCo IVD Holdings, LLC
60.60%
Renaissance Technologies LLC
4.64%
Hunter Associates Investment Management LLC
2.85%
Citadel Advisors LLC
1.07%
Two Sigma Investments, LP
0.98%
Otro
29.87%
Accionistas
Accionistas
Proporción
MiCo IVD Holdings, LLC
60.60%
Renaissance Technologies LLC
4.64%
Hunter Associates Investment Management LLC
2.85%
Citadel Advisors LLC
1.07%
Two Sigma Investments, LP
0.98%
Otro
29.87%
Tipos de accionistas
Accionistas
Proporción
Corporation
60.60%
Hedge Fund
6.69%
Investment Advisor
5.47%
Research Firm
0.71%
Investment Advisor/Hedge Fund
0.46%
Otro
26.08%

Participación institucional

Actualizado: jue., 1 de ene
Actualizado: jue., 1 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
52
2.76M
62.28%
+305.43K
2025Q3
51
972.36K
12.90%
+718.71K
2025Q2
50
3.17M
16.99%
-2.03M
2025Q1
53
3.13M
16.78%
-2.10M
2024Q4
50
4.89M
27.09%
-355.77K
2024Q3
47
4.97M
53.06%
-277.40K
2024Q2
45
4.94M
57.57%
-285.83K
2024Q1
44
5.20M
60.32%
-76.86K
2023Q4
40
3.94M
51.41%
+207.86K
2023Q3
42
3.97M
51.90%
+190.94K
Ver más

Actividad de los accionistas

Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
MiCo IVD Holdings, LLC
2.24M
60.6%
+1.79M
+400.00%
Dec 08, 2025
Renaissance Technologies LLC
171.36K
4.64%
+159.97K
+1404.10%
Sep 30, 2025
Hunter Associates Investment Management LLC
487.11K
13.19%
+399.53K
+456.18%
Sep 30, 2025
Citadel Advisors LLC
39.38K
1.07%
+39.38K
--
Sep 30, 2025
Two Sigma Investments, LP
36.23K
0.98%
+33.22K
+1101.76%
Sep 30, 2025
CAPTRUST Financial Advisors
27.25K
0.74%
+27.25K
--
Sep 30, 2025
Raymond James & Associates, Inc.
20.32K
0.55%
+15.25K
+300.77%
Sep 30, 2025
Williams & Novak Wealth Management, LLC
12.00K
0.32%
+7.60K
+172.73%
Sep 30, 2025
Becker Capital Management, Inc.
18.00K
0.49%
+14.40K
+400.00%
Sep 30, 2025
Geode Capital Management, L.L.C.
16.64K
0.45%
+13.31K
+400.06%
Sep 30, 2025
Ver más

ETFs relacionados

Nombre
Proporción
Sin datos

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos

División de acciones

Fecha
Fecha ex-dividendo
Tipo
Relación
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
Fecha
Fecha ex-dividendo
Tipo
Relación
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
Feb 13, 2024
Merger
5→1
KeyAI